Micafungin as primary antifungal prophylaxis in patients presenting withacute myeloid leukemia

authors

Venton Geoffroy
Adam Hélène H.
Colle J
Labiad Yasmine
Mercier Cédric
Ivanov Vadim
Suchon Pierre
Fanciullino Raphaelle
Farnault Laure
Costello Régis

keywords

Acute myeloid leukemia
Aspergillus
Micafungin

document type

ART

abstract

Objective. – To study the efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing inductionchemotherapy for acute myeloid leukemia.Patients and methods. – A prospective observational single-center study of 41 patients from the hematology department between May 2012 andApril 2015. Micafungin was administered once daily from the first day of induction chemotherapy to the end of the neutropenic phase.Results. – Neither Candida nor Aspergillus infection was documented in our 41 patients from the first day of micafungin infusion to the end ofthe neutropenic phase. Patients were followed for three months after discontinuation of micafungin and none of them contracted an invasive fungalinfection. Only one patient presented with grade III–IV hepatic and ionic toxicities.Conclusion. – Micafungin is associated with a good safety profile and is an interesting option for preventing invasive fungal infections in thehigh-risk population of patients presenting with hematological disorders.

more information